{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:38:52Z","timestamp":1793335132661,"version":"4.5.0"},"reference-count":16,"publisher":"American Society of Hematology","issue":"5","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Acute myeloid leukemia (AML) is a heterogeneous malignancy with outcomes largely predicted by genetic abnormalities. Mutations of NPM1 are common in AML, occurring in \u223c30% of cases, and generally considered a favorable risk factor. Mutations highly specific for secondary AML (sMut) have been shown to confer poor prognosis, but the overall impact of these mutations in the setting of favorable-risk AML defined by mutant NPM1 remains unclear. In this multicenter study of patients with AML (n\u00a0= 233) with NPM1 mutation at diagnosis, we observed that patients with sMut had worse overall survival (OS) than those without sMut (15.3 vs 43.7\u00a0months; P\u00a0= .002). Importantly, this finding persisted in the European LeukemiaNet (ELN) 2017\u2013defined favorable risk subset (14.7\u00a0months vs not reached; P\u00a0&amp;lt; .0001). Among patients who achieved NPM1 measurable residual disease (MRD) negativity, longer OS was observed in the entire cohort (P\u00a0= .015) as well as in both the sMut subset (MRD negative: median OS (mOS) 73.9\u00a0months vs MRD positive: 12.3\u00a0months; P\u00a0= .0170) and sMut ELN 2017\u2013favorable subset (MRD negative: mOS 27.3 vs MRD positive: 10.5\u00a0months; P\u00a0= .009). Co-occurrence of sMut and mutant NPM1 confers a poor prognosis in\u00a0AML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011173","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T13:47:52Z","timestamp":1704289672000},"page":"1075-1083","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":36,"title":["Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk\n                    <i>NPM1<\/i>\n                    -mutated AML"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2872-1961","authenticated-orcid":false,"given":"Onyee","family":"Chan","sequence":"first","affiliation":[{"name":"1Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najla","family":"Al Ali","sequence":"additional","affiliation":[{"name":"1Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2498-9111","authenticated-orcid":false,"given":"Hammad","family":"Tashkandi","sequence":"additional","affiliation":[{"name":"2Department of Hematopathology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Ellis","sequence":"additional","affiliation":[{"name":"2Department of Hematopathology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somedeb","family":"Ball","sequence":"additional","affiliation":[{"name":"1Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Grenet","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6663-3535","authenticated-orcid":false,"given":"Caroline","family":"Hana","sequence":"additional","affiliation":[{"name":"4Department of Malignant Hematology and Cellular Therapy at Memorial Healthcare System, Moffitt Cancer Center, Pembroke Pines, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Deutsch","sequence":"additional","affiliation":[{"name":"4Department of Malignant Hematology and Cellular Therapy at Memorial Healthcare System, Moffitt Cancer Center, Pembroke Pines, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-1458","authenticated-orcid":false,"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[{"name":"2Department of Hematopathology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Hussaini","sequence":"additional","affiliation":[{"name":"2Department of Hematopathology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Song","sequence":"additional","affiliation":[{"name":"2Department of Hematopathology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongseok","family":"Yun","sequence":"additional","affiliation":[{"name":"1Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetasi","family":"Talati","sequence":"additional","affiliation":[{"name":"1Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9040-7415","authenticated-orcid":false,"given":"Andrew","family":"Kuykendall","sequence":"additional","affiliation":[{"name":"1Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Padron","sequence":"additional","affiliation":[{"name":"1Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Walker","sequence":"additional","affiliation":[{"name":"1Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0384-3658","authenticated-orcid":false,"given":"Gail","family":"Roboz","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinkal","family":"Desai","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0504-8233","authenticated-orcid":false,"given":"David","family":"Sallman","sequence":"additional","affiliation":[{"name":"1Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra","family":"Sweet","sequence":"additional","affiliation":[{"name":"1Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-5269","authenticated-orcid":false,"given":"Rami","family":"Komrokji","sequence":"additional","affiliation":[{"name":"1Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Lancet","sequence":"additional","affiliation":[{"name":"1Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"issue":"15","key":"2024031115200902800_bib1","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood.2019004226","article-title":"NPM1-mutated acute myeloid leukemia: from bench to bedside","volume":"136","author":"Falini","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2024031115200902800_bib2","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/leu.2017.30","article-title":"Biological and clinical consequences of NPM1 mutations in AML","volume":"31","author":"Heath","year":"2017","journal-title":"Leukemia"},{"issue":"20","key":"2024031115200902800_bib3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"23","key":"2024031115200902800_bib4","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2024031115200902800_bib5","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1182\/blood-2005-08-3167","article-title":"Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)","volume":"107","author":"Thiede","year":"2006","journal-title":"Blood"},{"issue":"12","key":"2024031115200902800_bib6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2024031115200902800_bib7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2024031115200902800_bib8","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1038\/s41375-020-0872-3","article-title":"Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged &lt;60 years","volume":"34","author":"Eisfeld","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"2024031115200902800_bib9","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/ajh.25517","article-title":"The combination of NPM1, DNMT3A, and IDH1\/2 mutations leads to inferior overall survival in AML","volume":"94","author":"Dunlap","year":"2019","journal-title":"Am J Hematol"},{"issue":"9","key":"2024031115200902800_bib10","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"2024031115200902800_bib11","author":"R Core Team","year":"2020","edition":"4.0.2"},{"issue":"25","key":"2024031115200902800_bib12","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1182\/blood-2018-01-828467","article-title":"High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML","volume":"131","author":"Patel","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2024031115200902800_bib13","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2014.58.0571","article-title":"Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute\/Medical Research Council report","volume":"33","author":"Ostronoff","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"2024031115200902800_bib14","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2024031115200902800_bib15","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2024031115200902800_bib16","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N\u00a0Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/5\/1075\/2217596\/blooda_adv-2023-011173-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/5\/1075\/2217596\/blooda_adv-2023-011173-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T11:20:33Z","timestamp":1710156033000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/5\/1075\/506925\/Mutations-highly-specific-for-secondary-AML-are"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011173","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]}}}